Inclusion Criteria:

          -  Pathologically confirmed adenocarcinoma of the esophagus, GEJ or stomach.

          -  Stage IV disease or locally advanced/unresectable tumors

          -  Prior progression on only 1 line of chemotherapy in the advanced/metastatic setting
             containing a fluoropyrimidine and/or platinum compound

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

        Exclusion Criteria:

          -  Prior treatment with a taxane is not permitted in the dose-expansion phase. Patients
             in the dose escalation component may have received a taxane in the peri-operative
             setting, provided they developed disease recurrence >6 months after the completion of
             this therapy

          -  Known pre-existing liver disease (e.g. cirrhosis, chronic hepatitis B or C,
             nonalcoholic steatohepatitis, sclerosing cholangitis)

          -  Patients with any clinically apparent ascites or who have undergone a paracentesis
             within 7 days of enrollment

          -  Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm
             Hg on repeated measurement) despite optimal medical management

          -  Active or clinically significant cardiac disease

          -  Patients with arterial thrombotic events, such as cerebrovascular accident or
             myocardial infarction, within 6 months of enrollment